sars-cov-2 antigen rapid test
uses nasal swab specimens from individuals suspected of active covid-19 by their doctor within the first seven days of the onset of symptoms.
uses nasal swab specimens from individuals suspected of active covid-19 by their doctor within the first seven days of the onset of symptoms.
san diego, ca, september 17, 2020
acon laboratories, inc. announced the results of an independent evaluation of its acon sars-cov-2 igg/igm rapid test to be published in november. the article, including the results of the independent evaluation, is now available online at .